THROMBOSIS IN MYELOPROLIFERATIVE NEOPLASIA ASSOCIATED WITH DIFFERENT COAGULATION FACTOR POLYMORPHISMS
(Abstract release date: 05/19/16)
EHA Library. Dambrauskiene R. 06/09/16; 132907; E1358
Dr. Ruta Dambrauskiene
Contributions
Contributions
Abstract
Abstract: E1358
Type: Eposter Presentation
Background
The group of myeloproliferative neoplasms (MPNs) are known for their different phenotypes but similar vascular events complications. Blood cells, interaction between them, and the activation of coagulation factors play a role in the pathogenesis of thrombosis in MPNs. Platelet-specific polymorphisms, FVII as well as β-fibrinogen single nucleotide polymorphisms (SNP's) have been never analyzed together in patients with MPNs.
Aims
To evaluate the effects of coagulation factor VII, β-fibrinogen and TT genotype of GP c.807C>T single nucleotide polymorphisms, and the risk of thrombosis in patients with PV, ET, and PMF at the Department of Oncology and Hematology of the Institute of Oncology, the Lithuanian University of Health Sciences.
Methods
We included 108 patients in this survey. Findings of clinical and hematological analyses were collected. Genotyping was done using PCR and PCR-RFLP analysis
Results
TT genotype of GP c.807C>T polymorphism was more frequently found in the group of MPN patients with arterial thrombosis compared to the MPN patients who were thrombosis-free (26.5% vs. 11.5%, p=0.049). CT genotype of β-fibrinogen c.-148C>T polymorphism occurred significantly more frequently in MPN patients with arterial and total thrombosis compared to the wild type or homozygous genotype (respectively, 57.7% vs. 40.0 vs. 12.5%; p=0.027), (64.7% vs. 44.4% vs. 25% p=0.032). The carrier state for 323P10 variant of FVII SNP (summation of P10/10 and P0/10) was significantly more frequent in MPN patients with total thrombosis compared to the wild-type genotype carriers (71.4% vs. 43.4%, p=0.049). The coexistence of both genotypes - heterozygous β-fibrinogen c.-148C>T and FVII -323P0/10 SNP - statistically significantly increased the odds of arterial thrombosis in MNP patients (21.1% vs. 3.7%, p=0.008)
Conclusion
We found that 323P10 variant of FVII, TT genotype of GP c.807C>T and CT genotype of β-fibrinogen c.-148C>T SNP polymorphism may be associated with risk of thrombosis in patients with MPNs.
Session topic: E-poster
Keyword(s): Myeloid malignancies, Polymorphism, Thromboembolic events
Type: Eposter Presentation
Background
The group of myeloproliferative neoplasms (MPNs) are known for their different phenotypes but similar vascular events complications. Blood cells, interaction between them, and the activation of coagulation factors play a role in the pathogenesis of thrombosis in MPNs. Platelet-specific polymorphisms, FVII as well as β-fibrinogen single nucleotide polymorphisms (SNP's) have been never analyzed together in patients with MPNs.
Aims
To evaluate the effects of coagulation factor VII, β-fibrinogen and TT genotype of GP c.807C>T single nucleotide polymorphisms, and the risk of thrombosis in patients with PV, ET, and PMF at the Department of Oncology and Hematology of the Institute of Oncology, the Lithuanian University of Health Sciences.
Methods
We included 108 patients in this survey. Findings of clinical and hematological analyses were collected. Genotyping was done using PCR and PCR-RFLP analysis
Results
TT genotype of GP c.807C>T polymorphism was more frequently found in the group of MPN patients with arterial thrombosis compared to the MPN patients who were thrombosis-free (26.5% vs. 11.5%, p=0.049). CT genotype of β-fibrinogen c.-148C>T polymorphism occurred significantly more frequently in MPN patients with arterial and total thrombosis compared to the wild type or homozygous genotype (respectively, 57.7% vs. 40.0 vs. 12.5%; p=0.027), (64.7% vs. 44.4% vs. 25% p=0.032). The carrier state for 323P10 variant of FVII SNP (summation of P10/10 and P0/10) was significantly more frequent in MPN patients with total thrombosis compared to the wild-type genotype carriers (71.4% vs. 43.4%, p=0.049). The coexistence of both genotypes - heterozygous β-fibrinogen c.-148C>T and FVII -323P0/10 SNP - statistically significantly increased the odds of arterial thrombosis in MNP patients (21.1% vs. 3.7%, p=0.008)
Conclusion
We found that 323P10 variant of FVII, TT genotype of GP c.807C>T and CT genotype of β-fibrinogen c.-148C>T SNP polymorphism may be associated with risk of thrombosis in patients with MPNs.
Session topic: E-poster
Keyword(s): Myeloid malignancies, Polymorphism, Thromboembolic events
Abstract: E1358
Type: Eposter Presentation
Background
The group of myeloproliferative neoplasms (MPNs) are known for their different phenotypes but similar vascular events complications. Blood cells, interaction between them, and the activation of coagulation factors play a role in the pathogenesis of thrombosis in MPNs. Platelet-specific polymorphisms, FVII as well as β-fibrinogen single nucleotide polymorphisms (SNP's) have been never analyzed together in patients with MPNs.
Aims
To evaluate the effects of coagulation factor VII, β-fibrinogen and TT genotype of GP c.807C>T single nucleotide polymorphisms, and the risk of thrombosis in patients with PV, ET, and PMF at the Department of Oncology and Hematology of the Institute of Oncology, the Lithuanian University of Health Sciences.
Methods
We included 108 patients in this survey. Findings of clinical and hematological analyses were collected. Genotyping was done using PCR and PCR-RFLP analysis
Results
TT genotype of GP c.807C>T polymorphism was more frequently found in the group of MPN patients with arterial thrombosis compared to the MPN patients who were thrombosis-free (26.5% vs. 11.5%, p=0.049). CT genotype of β-fibrinogen c.-148C>T polymorphism occurred significantly more frequently in MPN patients with arterial and total thrombosis compared to the wild type or homozygous genotype (respectively, 57.7% vs. 40.0 vs. 12.5%; p=0.027), (64.7% vs. 44.4% vs. 25% p=0.032). The carrier state for 323P10 variant of FVII SNP (summation of P10/10 and P0/10) was significantly more frequent in MPN patients with total thrombosis compared to the wild-type genotype carriers (71.4% vs. 43.4%, p=0.049). The coexistence of both genotypes - heterozygous β-fibrinogen c.-148C>T and FVII -323P0/10 SNP - statistically significantly increased the odds of arterial thrombosis in MNP patients (21.1% vs. 3.7%, p=0.008)
Conclusion
We found that 323P10 variant of FVII, TT genotype of GP c.807C>T and CT genotype of β-fibrinogen c.-148C>T SNP polymorphism may be associated with risk of thrombosis in patients with MPNs.
Session topic: E-poster
Keyword(s): Myeloid malignancies, Polymorphism, Thromboembolic events
Type: Eposter Presentation
Background
The group of myeloproliferative neoplasms (MPNs) are known for their different phenotypes but similar vascular events complications. Blood cells, interaction between them, and the activation of coagulation factors play a role in the pathogenesis of thrombosis in MPNs. Platelet-specific polymorphisms, FVII as well as β-fibrinogen single nucleotide polymorphisms (SNP's) have been never analyzed together in patients with MPNs.
Aims
To evaluate the effects of coagulation factor VII, β-fibrinogen and TT genotype of GP c.807C>T single nucleotide polymorphisms, and the risk of thrombosis in patients with PV, ET, and PMF at the Department of Oncology and Hematology of the Institute of Oncology, the Lithuanian University of Health Sciences.
Methods
We included 108 patients in this survey. Findings of clinical and hematological analyses were collected. Genotyping was done using PCR and PCR-RFLP analysis
Results
TT genotype of GP c.807C>T polymorphism was more frequently found in the group of MPN patients with arterial thrombosis compared to the MPN patients who were thrombosis-free (26.5% vs. 11.5%, p=0.049). CT genotype of β-fibrinogen c.-148C>T polymorphism occurred significantly more frequently in MPN patients with arterial and total thrombosis compared to the wild type or homozygous genotype (respectively, 57.7% vs. 40.0 vs. 12.5%; p=0.027), (64.7% vs. 44.4% vs. 25% p=0.032). The carrier state for 323P10 variant of FVII SNP (summation of P10/10 and P0/10) was significantly more frequent in MPN patients with total thrombosis compared to the wild-type genotype carriers (71.4% vs. 43.4%, p=0.049). The coexistence of both genotypes - heterozygous β-fibrinogen c.-148C>T and FVII -323P0/10 SNP - statistically significantly increased the odds of arterial thrombosis in MNP patients (21.1% vs. 3.7%, p=0.008)
Conclusion
We found that 323P10 variant of FVII, TT genotype of GP c.807C>T and CT genotype of β-fibrinogen c.-148C>T SNP polymorphism may be associated with risk of thrombosis in patients with MPNs.
Session topic: E-poster
Keyword(s): Myeloid malignancies, Polymorphism, Thromboembolic events
{{ help_message }}
{{filter}}